Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Pathological complete response"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
Eun-Gyeong Lee, Dong-Eun Lee, Hyun hee Kim, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Youngmee Kwon, So-Youn Jung
Cancer Res Treat. 2023;55(2):542-550.   Published online September 8, 2022
DOI: https://doi.org/10.4143/crt.2022.834
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods
We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results
Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion
AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.

Citations

Citations to this article as recorded by  
  • The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response
    Di Ai, Eliel N Arrey, Lauren M Postlewait, Yuan Gao, Xiaoxian Li
    Histopathology.2025;[Epub]     CrossRef
  • Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
    Athina Stravodimou, Ioannis A. Voutsadakis
    Expert Review of Anticancer Therapy.2024; 24(3-4): 117.     CrossRef
  • Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
    Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang
    Scientific Reports.2024;[Epub]     CrossRef
  • Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma
    Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer
    Indian Journal of Surgical Oncology.2024; 15(4): 802.     CrossRef
  • Biomarkers and translational research approaches in breast cancer—an update
    Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
    memo - Magazine of European Medical Oncology.2023; 16(1): 42.     CrossRef
  • Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
    Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
    Discover Oncology.2023;[Epub]     CrossRef
  • 5,461 View
  • 178 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
Sanxing Guo, Sibylle Loibl, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Carsten Denkert
Cancer Res Treat. 2020;52(3):689-696.   Published online February 4, 2020
DOI: https://doi.org/10.4143/crt.2019.497
AbstractAbstract PDFPubReaderePub
Purpose
PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CAmutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.
Materials and Methods
A total of 92 patients with TNBC derived from a prospectively randomized phase II trial GeparSixto study (NCT01426880). Exon 9 and exon 20 of PIK3CA mutations were evaluated by using classical Sanger method with formalin-fixed paraffin-embedded tumor tissues.
Results
Seven of 90 tumors (7.8%) were detectable with a PIK3CA H1047R mutation. Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio, 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047). In carboplatin- containing treatment patients, H1047R mutation trended to predict a lower pCR rate (20% vs. 62.5%; p=0.146). In a multivariable analysis, H1047R mutation trended to predict a lower pCR rate (hazard ratio, 0.1; 95% CI, 0.01 to 1; p=0.056).
Conclusion
TNBC with a PIK3CA H1047R mutation was less likely to achieve pCR after anthracyclinebased neoadjuvant chemotherapy. Development of H1047R mutant selective inhibitors might be helpful to conquer this subtype of breast cancer.

Citations

Citations to this article as recorded by  
  • Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer
    Lisa Richters, Oleg Gluz, Nana Weber-Lassalle, Matthias Christgen, Heinz Haverkamp, Sherko Kuemmel, Mohamad Kayali, Ronald E. Kates, Eva-Maria Grischke, Janine Altmüller, Helmut Forstbauer, Holger Thiele, Michael Braun, Mathias Warm, Anna Ossowski, Rachel
    JAMA Network Open.2025; 8(2): e2461639.     CrossRef
  • Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study
    Jie Lian, Ru Yao, Siyuan Pang, Xinyu Ren, Bo Pan, Yidong Zhou
    Clinical Breast Cancer.2025;[Epub]     CrossRef
  • Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer
    Brian D. Lehmann, Vandana G. Abramson, E. Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs, Cesar A. Santa-Maria, Hanbing An, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Kimberly C. Newsom, Richard G. Abramson, Quanhu Sheng, Chih-Yuan H
    JAMA Oncology.2024; 10(2): 193.     CrossRef
  • Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment
    Elena Zaikova, Brian Y. C. Cheng, Viviana Cerda, Esther Kong, Daniel Lai, Amy Lum, Cherie Bates, Wendie den Brok, Takako Kono, Sylvie Bourque, Angela Chan, Xioalan Feng, David Fenton, Anagha Gurjal, Nathalie Levasseur, Caroline Lohrisch, Sarah Roberts, Ta
    npj Breast Cancer.2024;[Epub]     CrossRef
  • Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis
    Gabriela A. Martínez-Nava, Laura Keren Urbina-Jara, Saúl Lira-Albarrán, Henry L. Gómez, Erika Ruiz-García, María Tereza Nieto-Coronel, Rocio Ortiz-Lopez, Kenia Nadiezhda Martínez Villalba, Mariana Muñoz-Sánchez, Dione Aguilar, Liliana Gómez-Flores-Ramos,
    Diagnostics.2024; 14(3): 287.     CrossRef
  • Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
    John M. Ketcham, Stephen J. Harwood, Ruth Aranda, Athenea N. Aloiau, Briana M. Bobek, David M. Briere, Aaron C. Burns, Kersti Caddell Haatveit, Andrew Calinisan, Jeffery Clarine, Adam Elliott, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Benjamin Jone
    Journal of Medicinal Chemistry.2024; 67(6): 4936.     CrossRef
  • Prevalence and effect of PIK3CA H1047R somatic mutation among Indian head and neck cancer patients
    Arjita Ghosh, Anbalagan Moorthy
    Saudi Journal of Biological Sciences.2024; 31(8): 104029.     CrossRef
  • Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review
    Ehsan Mehrtabar, Amirreza Khalaji, Mojtaba Pandeh, Aram Farhoudian, Nadia Shafiee, Atefe Shafiee, Fatemeh Ojaghlou, Parinaz Mahdavi, Mehdi Soleymani-Goloujeh
    Medical Oncology.2024;[Epub]     CrossRef
  • Exploring the Inhibitory Efficacy of Resokaempferol and Tectochrysin on PI3Kα Protein by Combining DFT and Molecular Docking against Wild-Type and H1047R Mutant Forms
    Cristina Paraschiv, Steluța Gosav, Catalina Mercedes Burlacu, Mirela Praisler
    Inventions.2024; 9(5): 96.     CrossRef
  • Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis
    Xingxin Wang, Xuhao Li, Tiantian Dong, Wenyan Yu, Zhixia Jia, Yi Hou, Jiguo Yang, Yuanxiang Liu
    International Journal of Surgery.2024; 110(12): 7962.     CrossRef
  • Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
    Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu
    Journal of Personalized Medicine.2023; 13(2): 190.     CrossRef
  • Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
    Nadine S. van den Ende, Anh H. Nguyen, Agnes Jager, Marleen Kok, Reno Debets, Carolien H. M. van Deurzen
    International Journal of Molecular Sciences.2023; 24(3): 2969.     CrossRef
  • A light-up fluorescence platform based DNA: RNA hybrid G-quadruplet for detecting single nucleotide variant of ctDNA and miRNA-21
    Gaihua Cao, Keyi Long, Yue Qiu, Lan Peng, Haiyan Han, Yongzhong Wang, Danqun Huo, Changjun Hou
    Talanta.2023; 257: 124373.     CrossRef
  • Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
    Alexandre Bertucci, François Bertucci, Anthony Gonçalves
    Cancers.2023; 15(5): 1416.     CrossRef
  • Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
    Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno
    Biomedicines.2023; 11(3): 735.     CrossRef
  • Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation
    Bianca Lara Venâncio de Godoy, Marina Gobbe Moschetta-Pinheiro, Luiz Gustavo de Almeida Chuffa, Noam Falbel Pondé, Russel J. Reiter, Jucimara Colombo, Debora Aparecida Pires de Campos Zuccari
    Life Sciences.2023; 324: 121708.     CrossRef
  • Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions
    Nicholas Mai, Nour Abuhadra, Komal Jhaveri
    Clinical Breast Cancer.2023; 23(8): 784.     CrossRef
  • Role of epigenetics variation with focus on DNA methylation in triple-negative breast cancer patients
    GDeepthi Reddy, V Brahmaiah, BY Kavitha, Jayalatha Nethagani, ElizabethCaroline Palaparthi, RajasekharReddy Lebaka, G Deepika
    Archives of Medicine and Health Sciences.2023; 11(1): 96.     CrossRef
  • Potential Protective Role of Melatonin in Benign Mammary Cells Reprogrammed by Extracellular Vesicles from Malignant Cells
    Caroline Procópio de Oliveira, Barbara Maria Frigieri, Heidge Fukumasu, Luiz Gustavo de Almeida Chuffa, Adriana Alonso Novais, Debora Aparecida Pires de Campos Zuccari
    Biomedicines.2023; 11(10): 2837.     CrossRef
  • Role of Epigenetics Variation with Focus on DNA Methylation in Triple-Negative Breast Cancer Patients
    G. Deepthi Reddy, V. Brahmaiah, B. Y. Kavitha, Jayalatha Nethagani, Elizabeth Caroline Palaparthi, Rajasekhar Reddy Lebaka, G. Deepika
    Archives of Medicine and Health Sciences.2023; 11(1): 96.     CrossRef
  • Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature
    Juan C. Hernandez-Prera, Daryoush Saeed-Vafa, Amin Heidarian, Kathleen Gewandter, Kristen Otto, Bruce M. Wenig
    Head and Neck Pathology.2022; 16(2): 416.     CrossRef
  • PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness
    Cheila Brito, Ana Tomás, Ana Azevedo, Susana Esteves, Manuela Mafra, Lúcia Roque, Marta Pojo
    Clinical Medicine Insights: Oncology.2022;[Epub]     CrossRef
  • Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer
    Menghao Dong, Benjie Shan, Xinghua Han, Xiaotian Zhao, Fufeng Wang, Liuqing Zhu, Qiuxiang Ou, Xiaopeng Ma, Yueyin Pan
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
    Tatyana N. Sokolova, Tatyana I. Solov'eva, Svetlana N. Aleksakhina, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Aleksandr V. Shkradyuk, Yana S. Chapko, Anna A. Shchukina, Idris M. Khabr
    Journal of Modern Oncology.2022; 24(1): 12.     CrossRef
  • PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
    Liliana Ascione, Paola Zagami, Eleonora Nicolò, Edoardo Crimini, Giuseppe Curigliano, Carmen Criscitiello
    Journal of Personalized Medicine.2022; 12(11): 1793.     CrossRef
  • Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
    Fokhrul Hossain, Samarpan Majumder, Justin David, Lucio Miele
    Cancers.2021; 13(15): 3739.     CrossRef
  • Single-nucleotide variant of PIK3CA H1047R gene assay by CRISPR/Cas12a combined with rolling circle amplification
    Gaihua Cao, Xiaolong Chen, Yuanyi Deng, Fuping Nie, Yin Liu, Guoming Wang, Danqun Huo, Changjun Hou
    Analytica Chimica Acta.2021; 1182: 338943.     CrossRef
  • Identification of effective natural PIK3CA H1047R inhibitors by computational study
    Naimeng Liu, Xinhui Wang, Xuan Li, Xiaye Lv, Haoqun Xie, Zhen Guo, Jing Wang, Gaojing Dou, Ye Du, Dong Song
    Aging.2021; 13(16): 20246.     CrossRef
  • Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
    Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe,
    Nature Communications.2021;[Epub]     CrossRef
  • Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
    Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Muriele Bertagna Varuzza, Cassio Murilo Trovo Hidalgo Filho, Vinicius Duval da Silva, Cristiano de Pádua Souza, Márcia Maria Chiquitelli Marques
    Cancers.2021; 13(21): 5477.     CrossRef
  • Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis
    Wei Peng, Jian-Di Li, Jing-Jing Zeng, Xiao-Ping Zou, Deng Tang, Wei Tang, Min-Hua Rong, Ying Li, Wen-Bin Dai, Zhong-Qing Tang, Zhen-Bo Feng, Gang Chen
    Cancer Cell International.2020;[Epub]     CrossRef
  • Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease
    Amal Qattan
    International Journal of Molecular Sciences.2020; 21(23): 8905.     CrossRef
  • 10,086 View
  • 278 Download
  • 33 Web of Science
  • 32 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP